rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2015-0-6-142-142rentrad-91Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREВозможности бор-нейтронозахватной терапии в лечении злокачественных опухолей головного мозгаPossibilities of boron neutron capture therapy in the treatment of malignant brain tumorsКаныгинВ. В.KanyginV. V.

к. м. н., доцент кафедры нейрохирургии, вед. науч. сотр., нейрохирург, онколог

MD, PhD, Associate Professor of the Department of Neurosurgery,Leading Research Associate, Neurosurgeon, Oncologist

КичигинА. И.KichiginA. I.

стажер-исследователь, нейрохирург

Trainee Researcher, Neurosurgeon

ГубановаН. В.GubanovaN. V.

к. б. н., ст. науч. сотр.

PhD in Biol. Sci., Senior Research Associate

ТаскаевС. Ю.TaskaevS. Yu

д. ф.-м. н., вед. науч. сотр.

Dr. of Phys. and Math., Leading Research Associate

ГБОУ ВПО «Новосибирский государственный медицинский университет» Министерства здравоохранения РФ,ФГБУН «Институт ядерной физики им. Г.И. Будкера» Сибирского отделения Российской академии наук, НУЗ «Дорожная клиническая больница на ст. Новосибирск-Главный ОАО “РЖД”»РоссияNovosibirsk State Medical University, Ministry of Health of the RF, G.I. Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Road Clinical Hospital Station Novosibirsk-Main Open Joint Stock Company «Russian Railways»Russian FederationФГБУН «Институт ядерной физики им. Г.И. Будкера» Сибирского отделения Российской академии наук, НУЗ «Дорожная клиническая больница на ст. Новосибирск-Главный ОАО “РЖД”»РоссияG.I. Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Road Clinical Hospital Station Novosibirsk-Main Open Joint Stock Company «Russian Railways»Russian FederationФГБУН «Институт ядерной физики им. Г.И. Будкера» Сибирского отделения Российской академии наук, ФГБУН «Институт цитологии и генетики» Сибирского отделения Российской академии наук, ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»РоссияG.I. Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk State University National ResearchRussian FederationФГБУН «Институт ядерной физики им. Г.И. Будкера» Сибирского отделения Российской академии наук, ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»РоссияG.I. Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk State University National ResearchRussian Federation201509032016063642Copyright © Каныгин В.В., Кичигин А.И., Губанова Н.В., Таскаев С.Ю., 20162016Каныгин В.В., Кичигин А.И., Губанова Н.В., Таскаев С.Ю.Kanygin V.V., Kichigin A.I., Gubanova N.V., Taskaev S.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/91

Перспективным подходом в лечении онкологических заболеваний представляется бор-нейтронозахватная терапия (БНЗТ), это объясняется ее избирательным воздействием непосредственно на клетки злокачественных опухолей. Клинический интерес к БНЗТ в нейроонкологии сфокусирован на терапии глиом, в частности глиобластомы, также она может быть применена при метастатическом поражении головного мозга. Для этого необходим источник эпитепловых нейтронов, соответствующий требованиям БНЗТ, и 10В-содержащий препарат, который будет селективно накапливаться в опухолевой ткани. Внедрение метода БНЗТ в клиническуюпрактику у больных с глиальными опухолями позволит увеличить эффективность терапии.

Boron neutron capture therapy (BNCT) that is of the highest attractiveness due to its selective action directly on malignant tumor cells is a promising approach to treating cancers. Clinical interest in BNCT focuses in neuro-oncology on therapy for gliomas, glioblastoma in particular, and BNCT may be used in brain metastatic involvement. This needs an epithermal neutron source that complies with the requirements for BNCT, as wellas a 10B-containing agent that will selectively accumulate in tumor tissue. The introduction of BNCT into clinical practice to treat patients with glial tumors will be able to enhance therapeutic efficiency.

бор-нейтронозахватная терапияглиобластомаисточники нейтроновboron neutron capture therapyglioblastomaneutron sourcesReferencesLocher G.L. Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. Radium Ther. 1936; 36: 1–13.Locher G.L. Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. Radium Ther. 1936; 36: 1–13.Agosteo S. et al. Current status of neutron capture therapy. Vienna: IAEA; 2001.Agosteo S. et al. Current status of neutron capture therapy. Vienna: IAEA; 2001.Nakagava Y., Pooh K., Kobayashi T. et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beam. J. Neuro-Oncol. 2003; 62: 87–99.Nakagava Y., Pooh K., Kobayashi T. et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beam. J. Neuro-Oncol. 2003; 62: 87–99.Nakagava Y., Hatanaka Н. Boron neutron capture therapy: clinical brain tumor studies. J. Neurooncol. 1997; 33: 105–15.Nakagava Y., Hatanaka Н. Boron neutron capture therapy: clinical brain tumor studies. J. Neurooncol. 1997; 33: 105–15.Moss R. et al. Requirements for BNCT at a Nuclear Research Reactor – Results from a BNCT Workshop organized by the European Commission in Prague, November 2005//BNCT Workshop organized by the European Commission, Prague, 11–12 Nov. 2005: 582–4.Moss R. et al. Requirements for BNCT at a Nuclear Research Reactor – Results from a BNCT Workshop organized by the European Commission in Prague, November 2005//BNCT Workshop organized by the European Commission, Prague, 11–12 Nov. 2005: 582–4.Ohgaki H., Dessen P. et al. Genetic pathways to glioblastoma: a population- based study. Cancer Res. 2004; 64 (19): 6892–9.Ohgaki H., Dessen P. et al. Genetic pathways to glioblastoma: a population- based study. Cancer Res. 2004; 64 (19): 6892–9.Van Meir E.G., Hadjipanayis C.G. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. Cancer J. Clin. 2010; 60 (3): 166–93.Van Meir E.G., Hadjipanayis C.G. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. Cancer J. Clin. 2010; 60 (3): 166–93.Kita D., Yonekawa Y. et al. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007; 113 (3): 295–302.Kita D., Yonekawa Y. et al. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007; 113 (3): 295–302.Ekstrand A.J., Sugawa N. et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA. 1992; 89 (10): 4309–13.Ekstrand A.J., Sugawa N. et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA. 1992; 89 (10): 4309–13.Hulleman E., Helin K. Molecular mechanisms in gliomagenesis. Adv. Cancer Res. 2005; 94: 1–27.Hulleman E., Helin K. Molecular mechanisms in gliomagenesis. Adv. Cancer Res. 2005; 94: 1–27.Riesterer O., Milas L. et al. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J. Clin. Oncol. 2007; 25 (26): 4075–83.Riesterer O., Milas L. et al. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J. Clin. Oncol. 2007; 25 (26): 4075–83.Hopewell J.W., Gorlia T. et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl. Radiat. Isot. 2011; 69 (12): 1737–40.Hopewell J.W., Gorlia T. et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl. Radiat. Isot. 2011; 69 (12): 1737–40.Barth F., Vicente M.G.H., Harling O.K. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiation Oncology. 2012; 7: 146.Barth F., Vicente M.G.H., Harling O.K. et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiation Oncology. 2012; 7: 146.Soloway A.H., Tjarks W., Barnum B.A., Rong F.G., Barth R.F., Codogni I.M., Wilson J.G. The chemistry of neutron capture therapy. Chem. Rev. 1998; 98: 1515–62.Soloway A.H., Tjarks W., Barnum B.A., Rong F.G., Barth R.F., Codogni I.M., Wilson J.G. The chemistry of neutron capture therapy. Chem. Rev. 1998; 98: 1515–62.Kubota R., Yamada S. et al. Cellular accumulation of 18F-labelled boronophenylalanine depending on DNA synthesis and melanin incorporation: a double-tracer microautoradiographic study of B16 melanomas in vivo. Br. J. Cancer. 1993; 67 (4): 701–5.Kubota R., Yamada S. et al. Cellular accumulation of 18F-labelled boronophenylalanine depending on DNA synthesis and melanin incorporation: a double-tracer microautoradiographic study of B16 melanomas in vivo. Br. J. Cancer. 1993; 67 (4): 701–5.Yang F.Y., Chen Y.W. et al. Boron neutron capture therapy for glioblastoma multiforme: enhanced drug delivery and antitumor effect following blood-brain barrier disruption induced by focused ultrasound. Future Oncol. 2012; 8 (10): 1361–9.Yang F.Y., Chen Y.W. et al. Boron neutron capture therapy for glioblastoma multiforme: enhanced drug delivery and antitumor effect following blood-brain barrier disruption induced by focused ultrasound. Future Oncol. 2012; 8 (10): 1361–9.Kraft S.L., Gavin P.R. et al. Borocaptate sodium: a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc. Natl. Acad. Sci. USA. 1992; 89 (24): 11973–7.Kraft S.L., Gavin P.R. et al. Borocaptate sodium: a potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc. Natl. Acad. Sci. USA. 1992; 89 (24): 11973–7.Semioshkin A., Laskova J., Zhidkova O., Godovikov I., Starikova Z., Bregadze V.I., Gabel D. Synthesis and structure of novel closo-dodecaborate-based glycerols. J. Organomet. Chem. 2010; 695: 370–4.Semioshkin A., Laskova J., Zhidkova O., Godovikov I., Starikova Z., Bregadze V.I., Gabel D. Synthesis and structure of novel closo-dodecaborate-based glycerols. J. Organomet. Chem. 2010; 695: 370–4.Olsson Р. et al. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGFreceptor expression. Anticancer Drug. Des. 1998; 13: 279–89.Olsson Р. et al. Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGFreceptor expression. Anticancer Drug. Des. 1998; 13: 279–89.Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug. Deliv. Rev. 2011; 63 (3): 136–51.Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug. Deliv. Rev. 2011; 63 (3): 136–51.Doijad R.C., Bhambere D.S., Manvi F.V., Deshmukh N.V. Formulation and characterization of vesicular drug delivery system for anti-HIV drug. J. Global. Pharma Technology. 2009; 1 (1): 94–100.Doijad R.C., Bhambere D.S., Manvi F.V., Deshmukh N.V. Formulation and characterization of vesicular drug delivery system for anti-HIV drug. J. Global. Pharma Technology. 2009; 1 (1): 94–100.Maurer N., Fenske D.B., Cullis P.R. Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. 2001; 1 (5): 1–25.Maurer N., Fenske D.B., Cullis P.R. Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. 2001; 1 (5): 1–25.Hawthorne M.F., Shelly K. Liposomes as drug delivery vehicles for boron agents. J. Neurooncol. 1997; 33 (1–2): 53–8.Hawthorne M.F., Shelly K. Liposomes as drug delivery vehicles for boron agents. J. Neurooncol. 1997; 33 (1–2): 53–8.Nakamura H., Miyajima Y. et al. Synthesis and vesicle formation of a nido-carborane cluster lipid for boron neutron capture therapy. Chem. Commun. (Camb). 2004; 17: 1910–1.Nakamura H., Miyajima Y. et al. Synthesis and vesicle formation of a nido-carborane cluster lipid for boron neutron capture therapy. Chem. Commun. (Camb). 2004; 17: 1910–1.Ueno M., Ban H.S. et al. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy. Bioorg Med. Chem. 2010; 18 (9): 3059–65.Ueno M., Ban H.S. et al. Dodecaborate lipid liposomes as new vehicles for boron delivery system of neutron capture therapy. Bioorg Med. Chem. 2010; 18 (9): 3059–65.Pan X.Q., Wang H. et al. Boroncontaining folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem. 2002; 13 (3): 435–42.Pan X.Q., Wang H. et al. Boroncontaining folate receptor-targeted liposomes as potential delivery agents for neutron capture therapy. Bioconjug Chem. 2002; 13 (3): 435–42.Pan X., Wu G. et al. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem. 2007; 18 (1): 101–8.Pan X., Wu G. et al. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem. 2007; 18 (1): 101–8.Kueffer P.J., Maitz C.A., Khan A.A., Schuster S.A., Shlyakhtina N.I., Jalisatgi S.S. et al. Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes. Proceed. Nation. Acad. Sci. USA. 2013; 110 (16): 6512–7.Kueffer P.J., Maitz C.A., Khan A.A., Schuster S.A., Shlyakhtina N.I., Jalisatgi S.S. et al. Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes. Proceed. Nation. Acad. Sci. USA. 2013; 110 (16): 6512–7.Tanaka H., Sakurai Y., Suzuki M. et al. Experimental verification of beam characteristics for cyclotronbased epithermal neutron source (C-BENS). Applied Radiat. Isotop. 2011; 69: 1642–5.Tanaka H., Sakurai Y., Suzuki M. et al. Experimental verification of beam characteristics for cyclotronbased epithermal neutron source (C-BENS). Applied Radiat. Isotop. 2011; 69: 1642–5.Yoshioka M. et al. Construction of accelerator-based BNCR facility at Ibaraki Neutron Medical Research Center. 16th International Congress on Neutron Capture Therapy, June 14–19, 2014, Helsinki, Finland (www.icnct16.org): 66.Yoshioka M. et al. Construction of accelerator-based BNCR facility at Ibaraki Neutron Medical Research Center. 16th International Congress on Neutron Capture Therapy, June 14–19, 2014, Helsinki, Finland (www.icnct16.org): 66.Bayanov B. et al. Accelerator based neutron source for the neutroncapture and fast neutron therapy at hospital. Nucl. Instrum. Meth. Phys. Res. A. 1998; 413 (2–3): 397–426.Bayanov B. et al. Accelerator based neutron source for the neutroncapture and fast neutron therapy at hospital. Nucl. Instrum. Meth. Phys. Res. A. 1998; 413 (2–3): 397–426.Таскаев С.Ю. Ускорительный источник эпитепловых нейтро-нов: Дис. … д-ра физ.-мат. наук. Новосибирск; 2014. URL: http://www. inp.nsk.su/news/defences/Taskaev_diss.pdf/ Taskaev S.Yu.Accelerator based epithermal neutronsource: Dr. of Phys. And Math. sci. Diss. Novosibirsk; 2014. URL: http://www.inp.nsk.su/news/defences/Taskaev_diss.pdf (in Russian).Таскаев С.Ю. Ускорительный источник эпитепловых нейтро-нов: Дис. … д-ра физ.-мат. наук. Новосибирск; 2014. URL: http://www. inp.nsk.su/news/defences/Taskaev_diss.pdf/ Taskaev S.Yu.Accelerator based epithermal neutronsource: Dr. of Phys. And Math. sci. Diss. Novosibirsk; 2014. URL: http://www.inp.nsk.su/news/defences/Taskaev_diss.pdf (in Russian).Kasatov D. et al. Proton beam of 2 MeV 1.6 mA on a tandem accelerator with vacuum insulation. J. Instrument. 2014; 9: 12016.Kasatov D. et al. Proton beam of 2 MeV 1.6 mA on a tandem accelerator with vacuum insulation. J. Instrument. 2014; 9: 12016.Таскаев C.Ю., Каныгин В.В. Система формирования пучка нейтронов. Патент РФ на изобретение № 2540124 от 16.12.2014./ Taskaev S.Yu., Kanygin V.V. Neutron beam shaping assembly. Patent RF № 2540124; 16.12.2014 (in Russian).Таскаев C.Ю., Каныгин В.В. Система формирования пучка нейтронов. Патент РФ на изобретение № 2540124 от 16.12.2014./ Taskaev S.Yu., Kanygin V.V. Neutron beam shaping assembly. Patent RF № 2540124; 16.12.2014 (in Russian).

The authors declare that there are no conflicts of interest present.